Neeraj Agarwal, MD
It has been a revolutionary year of therapeutic developments for the treatment of newly diagnosed patients with renal cell carcinoma (RCC), explains Neeraj Agarwal, MD.
on Genitourinary Cancers, Agarwal, an associate professor in the Division of Oncology, Department of Medicine, director of the Genitourinary Medical Oncology Program, Huntsman Cancer Institute at the University of Utah, recapped the latest advancements in newly diagnosed RCC. In an interview, he shed more insight on these pivotal clinical trial findings and what the future of this landscape holds.
OncLive: Can you please provide an overview of your lecture?
As you know, the treatment in newly diagnosed patients with RCC has undergone, literally, a revolution in the last year. Until very recently, we have had only 2 drugs—sunitinib and pazopanib (Votrient), which were considered standard of care for these patients. This is going to be transformed by 2 clinical trials that have been presented within the last year.
... to read the full story